Vanda Pharmaceuticals Inc. (VNDA) reported the results from second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. Vanda expects to submit a NDA for tradipitant in the prevention of vomiting induced by motion to the FDA in the fourth quarter of 2024.
The Motion Serifos study was a multicenter double-blind, placebo-controlled study where 316 participants received tradipitant 170 mg, tradipitant 85 mg, or placebo. Both 170 mg and 85 mg tradipitant doses were shown to be superior to placebo in preventing vomiting.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.